Newsroom | 45267 results
Sorted by: Latest
-
Anthem Establishes Coverage of C2N Diagnostics’ PrecivityAD2® Blood Test for Alzheimer's Disease Evaluation
ST. LOUIS--(BUSINESS WIRE)--C2N Diagnostics, LLC ("C2N"), a specialty diagnostics company with a vision to bring Clarity Through Innovation®, announced that beginning October 1, 2026, eligible Anthem® Blue Cross® and Blue Shield® members will be the first in the United States to receive insurance coverage under a medical policy for the PrecivityAD2® blood test. This policy expands patient access to an innovative blood-based diagnostic test that helps health care professionals evaluate adults exp...
-
Care.com Appoints Chekesha Kidd as General Manager of CareBenefits by Care.com
DALLAS--(BUSINESS WIRE)--Care.com today announced the appointment of Chekesha Kidd as General Manager of CareBenefits by Care.com, the company's employer benefits division helping working families access care support for children, aging parents, and household needs. Kidd brings more than 20 years of senior leadership experience across the employee benefits industry, including roles at Aetna, Delta Dental of Minnesota, and The Hartford, and most recently founded Kinumi, a health and lifestyle pl...
-
LEO Pharma Announces Key Results of Phase 2 TRAPEDS-1 Trial Evaluating Pharmacokinetics and Safety of Tralokinumab in Children With Moderate-to-Severe Atopic Dermatitis
BALLERUP, Denmark--(BUSINESS WIRE)--LEO Pharma announces key results of Phase 2 TRAPEDS-1 trial evaluating pharmacokinetics and safety of tralokinumab...
-
Independent Recognition Reinforces Auragens' Position as a Global Leader in Regenerative Medicine
LAS VEGAS & PANAMA CITY, Panama--(BUSINESS WIRE)--Auragens today announced it has been named Stem Cell Treatment Center of the Year 2026 by Life Sciences Review, becoming the first organization to receive the publication's highest distinction for two consecutive years. While the award recognizes excellence in patient care, it also reflects a broader transformation taking place within regenerative medicine—one in which scientific rigor, manufacturing quality, regulatory oversight, and integrated...
-
Maryland Tech Council Announces New Board of Directors
ROCKVILLE, Md.--(BUSINESS WIRE)--The Maryland Tech Council (MTC), the largest technology and life sciences trade association in the state, today announced the election of new members to its Board of Directors. Bringing decades of expertise across technology, life sciences, and related industries, the directors will help guide MTC’s strategy and planning for the 2-year term. "We are excited to collaborate with this dynamic group of new board members," said Kelly Schulz, CEO of the Maryland Tech...
-
Arialys Therapeutics Announces U.S. FDA Fast Track Designation for ART5803, the First Precision Therapeutic Candidate in Development for the Treatment of Anti-NMDA Receptor Encephalitis
LA JOLLA, Calif.--(BUSINESS WIRE)--Arialys Announces U.S. FDA Fast Track Designation for ART5803, the First Precision Therapeutic Candidate in Development for the Treatment of ANRE...
-
Vega Health and Baptist Health Bring Actionable AI to Hospital at Home, Set Foundation for Long-Term Collaboration
DURHAM, N.C.--(BUSINESS WIRE)--Announcing a partnership between Vega Health and Baptist Health Jacksonville, a multi-hospital health system based in the Southeast...
-
VB Spine’s European Distribution Center Begins Shipping Orders Across Europe
NEW YORK--(BUSINESS WIRE)--VB Spine LLC (“VB Spine”), a global, family-owned spine company, today announced that its European Distribution Center began shipping orders across Europe this month; the distribution center began accepting orders on June 1, 2026. Now that the center is fully operational, it serves as the primary center for VB Spine product distribution to customers in Europe. “The center allows us to support our customers more effectively by reducing fulfillment and response times,”...
-
Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis
TEL AVIV, Israel & ZUG, Switzerland--(BUSINESS WIRE)--Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd (NYSE: and TASE: TEVA) and Polpharma Biologics International AG today announced a global licensing agreement granting Teva exclusive rights to commercialize both formulations of Polpharma Biologics’ proposed biosimilar to Ocrevus®1 (ocrelizumab), upon regulatory approval. This strategic agreement is expected to combine Polpharma Biologics’ proven bios...
-
ClearNote Health Announces Leadership Transition
SAN DIEGO--(BUSINESS WIRE)--ClearNote Health announced Kevin Keegan, currently president and chief operating officer, has been appointed CEO, effective July 31, 2026....